Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Oxford Nanopore H1 revenues and profits surge
(Sharecast News) - Molecular sensing technology outfit Oxford Nanopore Technologies said on Tuesday that both revenues and profits had surged in the six months ended 30 June, primarily driven by increased life science research tools revenues. Group revenues were up 107% on a reported basis at £122.3m, with LSRT revenues growing 34% to £70.6m, primarily driven by increasing customer numbers, and non-recurring Covid-19 testing revenues shooting up 709% to £51.8m.
Gross profits rose 158% to £78.0m and gross margins increased 12.5 points to 63.7%.
Adjusted underlying losses widened by £15.4m to £34.6m, as higher LSRT gross profits were offset by increased operating expenses, while the group's overall loss for the period narrowed by £14.6m to £30.2m.
Cash and cash equivalents and Treasury deposits of £602.6m were down slightly from £618.2m as of 31 December 2021.
Looking forward, Oxford Nanopore said year-to-date trading was in line with expectations, with the group expecting full year 2022 LSRT revenues to be in the range of £145.0m to £160.0m.
The AIM-listed group also noted that full-year revenue guidance already accounted for an expected tapering of Covid-19 sequencing revenues in the second half of the year and an anticipated drop in Emirati Genome Program revenues of £15.0m to £20.0m - lower than previously forecast.
As of 1015 BST, Oxford Nanopore shares were up 2.21% at 278.0p.
Reporting by Iain Gilbert at Sharecast.com
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.